• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

奥司他韦治疗对门诊流感症状的影响：一项随机试验的结果。

Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial.

机构信息

Center for Clinical Epidemiology and Population Health.

Integrated Research and Development Laboratory , Marshfield Clinic Research Foundation , Wisconsin.

出版信息

Open Forum Infect Dis. 2015 Jul 8;2(3):ofv100. doi: 10.1093/ofid/ofv100. eCollection 2015 Sep.

DOI:10.1093/ofid/ofv100
PMID:26258157
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4525010/
Abstract

We conducted a double-blind, randomized trial of 134 outpatients with polymerase chain reaction-confirmed influenza to assess the effects of oseltamivir initiated 48-119 hours after illness onset. Oseltamivir treatment did not reduce illness duration, severity, or duration of virus detection. However, the power of this study was limited due to lower than expected enrollment.

摘要

我们对 134 名经聚合酶链反应确诊的流感门诊患者进行了一项双盲、随机试验，以评估在发病后 48-119 小时开始奥司他韦治疗的效果。奥司他韦治疗并未缩短疾病持续时间、减轻疾病严重程度或缩短病毒检测时间。然而，由于入组人数低于预期，本研究的效能受到限制。

相似文献

1
Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial.奥司他韦治疗对门诊流感症状的影响：一项随机试验的结果。
Open Forum Infect Dis. 2015 Jul 8;2(3):ofv100. doi: 10.1093/ofid/ofv100. eCollection 2015 Sep.
2
Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.在孟加拉国的城市环境中，奥司他韦治疗开始于症状出现后 5 天内可减少流感疾病持续时间和病毒脱落：一项随机安慰剂对照试验。
Lancet Infect Dis. 2014 Feb;14(2):109-18. doi: 10.1016/S1473-3099(13)70267-6. Epub 2013 Nov 22.
3
Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.口服神经氨酸酶抑制剂奥司他韦治疗急性流感的疗效与安全性：一项随机对照试验。美国口服神经氨酸酶研究组。
JAMA. 2000 Feb 23;283(8):1016-24. doi: 10.1001/jama.283.8.1016.
4
Effects of oseltamivir treatment of index patients with influenza on secondary household illness in an urban setting in Bangladesh: secondary analysis of a randomised, placebo-controlled trial.孟加拉国城市环境中奥司他韦治疗流感首发患者对家庭二代发病的影响：一项随机、安慰剂对照试验的二次分析。
Lancet Infect Dis. 2015 Jun;15(6):654-62. doi: 10.1016/S1473-3099(15)70041-1. Epub 2015 Mar 16.
5
[Efficacy and safety of oseltamivir in children with suspected influenza: a multicenter randomized open-label trial].[奥司他韦治疗疑似流感儿童的疗效与安全性：一项多中心随机开放标签试验]
Zhonghua Er Ke Za Zhi. 2017 Jun 2;55(6):462-467. doi: 10.3760/cma.j.issn.0578-1310.2017.06.014.
6
Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial.连花清瘟胶囊治疗甲型 H1N1 流感随机、双盲、阳性药对照临床研究
Chin Med J (Engl). 2011 Sep;124(18):2925-33.
7
A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama.一项在萨尔瓦多和巴拿马进行的随机、双盲、安慰剂对照试验，评估0至9岁因流感住院儿童早期使用奥司他韦治疗的安全性。
Antiviral Res. 2016 Sep;133:85-94. doi: 10.1016/j.antiviral.2016.07.007. Epub 2016 Jul 21.
8
Neuraminidase inhibitors for preventing and treating influenza in children.用于预防和治疗儿童流感的神经氨酸酶抑制剂。
Cochrane Database Syst Rev. 2012 Jan 18;1:CD002744. doi: 10.1002/14651858.CD002744.pub3.
9
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.巴洛沙韦玛波西利治疗成人和青少年单纯性流感。
N Engl J Med. 2018 Sep 6;379(10):913-923. doi: 10.1056/NEJMoa1716197.
10
Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial.奥司他韦在预防家庭接触者流感方面的有效性：一项随机对照试验。
JAMA. 2001 Feb 14;285(6):748-54. doi: 10.1001/jama.285.6.748.

引用本文的文献

1
MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies.miRNA 与 SARS-CoV-2 的对话和潜在的抗 COVID-19 疗法。
Life Sci. 2022 Sep 15;305:120761. doi: 10.1016/j.lfs.2022.120761. Epub 2022 Jul 1.
2
The impact of the COVID-19 pandemic on the global burden of influenza.2019年冠状病毒病大流行对全球流感负担的影响。
J Med Virol. 2022 Jun;94(6):2357-2359. doi: 10.1002/jmv.27653. Epub 2022 Feb 17.
3
Anti-SARS-CoV-2 Strategies and the Potential Role of miRNA in the Assessment of COVID-19 Morbidity, Recurrence, and Therapy.抗 SARS-CoV-2 策略及 miRNA 在评估 COVID-19 发病、复发和治疗中的潜在作用。
Int J Mol Sci. 2021 Aug 12;22(16):8663. doi: 10.3390/ijms22168663.
4
Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection.伊维菌素在治疗和预防 SARS-CoV-2 感染方面的潜在用途。
Curr Res Transl Med. 2021 Oct;69(4):103309. doi: 10.1016/j.retram.2021.103309. Epub 2021 Aug 11.
5
Enisamium Reduces Influenza Virus Shedding and Improves Patient Recovery by Inhibiting Viral RNA Polymerase Activity.依昔莫单抗可通过抑制病毒 RNA 聚合酶活性来减少流感病毒脱落并改善患者康复情况。
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02605-20.
6
Possible Role of Adenosine in COVID-19 Pathogenesis and Therapeutic Opportunities.腺苷在新冠病毒疾病发病机制中的潜在作用及治疗机会
Front Pharmacol. 2020 Nov 26;11:594487. doi: 10.3389/fphar.2020.594487. eCollection 2020.
7
MicroRNA Biomarkers for Infectious Diseases: From Basic Research to Biosensing.用于传染病的微小RNA生物标志物：从基础研究到生物传感
Front Microbiol. 2020 Jun 3;11:1197. doi: 10.3389/fmicb.2020.01197. eCollection 2020.
8
A Broad and Potent H1-Specific Human Monoclonal Antibody Produced in Plants Prevents Influenza Virus Infection and Transmission in Guinea Pigs.一种广谱且高效的 H1 型特异性人源单克隆抗体在植物中表达，可预防豚鼠感染和传播流感病毒。
Viruses. 2020 Feb 2;12(2):167. doi: 10.3390/v12020167.
9
Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.ALX-0171 与帕利珠单抗治疗呼吸道合胞病毒临床分离株感染分化良好的原代小儿支气管上皮细胞培养物的比较治疗潜力。
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.02034-19.

本文引用的文献

1
Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.在孟加拉国的城市环境中，奥司他韦治疗开始于症状出现后 5 天内可减少流感疾病持续时间和病毒脱落：一项随机安慰剂对照试验。
Lancet Infect Dis. 2014 Feb;14(2):109-18. doi: 10.1016/S1473-3099(13)70267-6. Epub 2013 Nov 22.
2
Clinical and virologic outcomes in patients with oseltamivir-resistant seasonal influenza A (H1N1) infections: results from a clinical trial.奥司他韦耐药季节性甲型 H1N1 流感病毒感染患者的临床和病毒学结局：一项临床试验的结果。
Influenza Other Respir Viruses. 2012 May;6(3):153-8. doi: 10.1111/j.1750-2659.2011.00312.x. Epub 2011 Nov 26.
3
Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and final results.2007-08 年度威斯康星州流感疫苗效力：中期和最终结果比较。
Vaccine. 2011 Sep 2;29(38):6558-63. doi: 10.1016/j.vaccine.2011.07.002. Epub 2011 Jul 19.
4
Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP).抗流感病毒药物的治疗和化学预防 --- 免疫实践咨询委员会（ACIP）的建议。
MMWR Recomm Rep. 2011 Jan 21;60(1):1-24.
5
Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial.1-3 岁儿童流感的早期奥司他韦治疗：一项随机对照试验。
Clin Infect Dis. 2010 Oct 15;51(8):887-94. doi: 10.1086/656408.
6
Early administration of oral oseltamivir increases the benefits of influenza treatment.早期口服奥司他韦可增加流感治疗的获益。
J Antimicrob Chemother. 2003 Jan;51(1):123-9. doi: 10.1093/jac/dkg007.
7
Oral oseltamivir treatment of influenza in children.口服奥司他韦治疗儿童流感。
Pediatr Infect Dis J. 2001 Feb;20(2):127-33. doi: 10.1097/00006454-200102000-00002.
8
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.奥司他韦治疗急性流感的疗效与安全性：一项随机对照试验。神经氨酸酶抑制剂流感治疗研究组。
Lancet. 2000 May 27;355(9218):1845-50. doi: 10.1016/s0140-6736(00)02288-1.
9
Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.口服神经氨酸酶抑制剂奥司他韦治疗急性流感的疗效与安全性：一项随机对照试验。美国口服神经氨酸酶研究组。
JAMA. 2000 Feb 23;283(8):1016-24. doi: 10.1001/jama.283.8.1016.